ClinicalTrials.gg
RecruitingNCT07198152Updated Sep 30, 2025

Artificial Intelligence Used in Screening Adrenal Nodules

An observational study in Adrenal Incidentalomas and Thoracic CT-scan, sponsored by Peking University First Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-30.

Sponsored by Peking University First Hospital · Observational

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Retrospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Study summary

By collecting chest low-dose spiral CT plain scan images, extracting effective features from the adrenal gland regions, training and validating an artificial intelligence-based automatic diagnostic algorithm for adrenal nodules, we will ultimately develop an artificial intelligence software with independent intellectual property rights that is specifically designed for screening adrenal nodules in chest low-dose CT scans.

02

Conditions studied

  • Adrenal Incidentalomas
  • Thoracic CT-scan

Browse trials for

Keywords

  • automatic segment; automatic classification
03

In context

Adrenal incidentaloma

27 studies on the registry are indexed under Adrenal incidentaloma; 12 are open to participants now.

This study's planned enrollment of 600 is above the median of 300 across 18 observational studies indexed under Adrenal incidentaloma.

Browse Adrenal incidentaloma studies →

Lead sponsor

Peking University First Hospital is the lead sponsor of 393 studies on the registry; 188 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The study population consists of individuals aged over 18 years, with no gender restrictions, who underwent chest low-dose CT scans as part of routine physical examinations. Notably, those with a history of malignant tumors are excluded, and only individuals with qualified imaging data (free from poor quality, artifacts, or other issues that hinder analysis) are included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The age of the population is over 18 years old, regardless of gender;
  2. Images from chest low-dose CT plain scan during routine physical examination;

Exclusion criteria

Exclusion Criteria:

  1. Patients with a history of malignant tumors;
  2. Imaging images with poor quality, artifacts, etc., which make analysis impossible.
05

Study design

Observational model
Ecologic or community
Time perspective
Retrospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Nodular adrenal glands

    Adrenal region segmentation and adrenal nodule identification in chest CT via artificial intelligence

    Other: None intervention

  • Normal adrenal glands

    Adrenal region delineation and adrenal gland identification in chest CT using artificial intelligence

    Other: None intervention

Interventions

  • OtherNone intervention

    this study is retrospective based on the CT images, which dose include any intervention.

06

What researchers measure

Primary outcomes

  1. Overall Diagnostic Accuracy

    Time frame: From enrollment to the end of collection in one and a half years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Dec 2026, 15 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Sep 30, 2025
StartActual
Sep 1, 2025
Primary completionEst.
Dec 30, 2026
CompletionEst.
Jan 30, 2027
Last update
Sep 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07198152
Responsible party
Sponsor
First posted
Sep 30, 2025
Start date
Sep 1, 2025
Primary completion
Dec 30, 2026 (estimated)
Completion
Jan 30, 2027 (estimated)
Last update
Sep 30, 2025

Study contacts

Shiwei Chen
Contact
15914944390@163.com
+86 159 1494 4390

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion